Praluent Cost in Indiana 2026: Prices, Insurance, Medicaid, and Compounding Options

What Alirocumab (Praluent) Is and Why It Matters for Indiana Patients

Alirocumab is a fully human monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, alirocumab increases the number of functional LDL receptors and lowers LDL-C by 45 to 60 percent in most patients. The FDA approved Praluent in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on maximally tolerated statin therapy. The full Praluent prescribing information is available from the FDA.

Indiana's cardiovascular disease burden makes access especially relevant. According to the CDC, Indiana ranks among the top 15 states for age-adjusted coronary heart disease mortality, with rates consistently above the national median. CDC Heart Disease State Data. Patients with HeFH or post-MI LDL that remains above 70 mg/dL on high-intensity statins represent the core population for whom cardiologists and lipidologists will consider a PCSK9 inhibitor such as alirocumab.

The standard dosing schedule is 75 mg subcutaneously every two weeks, with an option to titrate to 150 mg every two weeks if LDL-C reduction is insufficient after four weeks of therapy. A 300 mg dose given once monthly is also available for some patients requiring long-term maintenance.

Praluent List Price and Cash-Pay Costs in Indiana in 2026

The Regeneron/Sanofi wholesale acquisition cost for Praluent has remained near $580 per month through 2026 for a standard every-two-week regimen. That figure represents the list price most Indiana retail pharmacies will quote to an uninsured or out-of-network patient. No meaningful discount exists at chains such as CVS, Walgreens, or Kroger Health without an insurance claim or a manufacturer coupon.

GoodRx and similar coupon aggregators occasionally show prices 5 to 15 percent below list for alirocumab at select Indiana ZIP codes, but the range is narrow because Praluent lacks generic competition. A 30-day supply at major Indiana pharmacies (Indianapolis, Fort Wayne, Evansville, South Bend) consistently falls between $560 and $600 cash-pay in early 2026.

For patients with no coverage and no access to compounding, an annual out-of-pocket cost of roughly $6,960 to $7,200 is realistic. That number excludes the cost of the required follow-up lipid panels, typically drawn four to eight weeks after initiation per ACC/AHA 2019 cholesterol guideline recommendations. ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease via PubMed.

The Clinical Evidence Behind the Price Tag

The ODYSSEY OUTCOMES trial enrolled 18,924 patients who had experienced a recent acute coronary syndrome and remained above LDL-C targets on high-intensity statin therapy. At a median follow-up of 2.8 years, alirocumab reduced the primary composite endpoint (coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization) by 15 percent relative to placebo (HR 0.85; 95% CI 0.78 to 0.93; P<0.001). Mean LDL-C at 48 months was 53.3 mg/dL in the alirocumab group versus 101.4 mg/dL in the placebo group. ODYSSEY OUTCOMES full text, NEJM 2018.

A pre-specified subgroup analysis from ODYSSEY OUTCOMES found that patients with baseline LDL-C at or above 100 mg/dL derived the largest absolute risk reduction: 3.4 percentage points at 4 years, corresponding to a number needed to treat of 29 over that period. ODYSSEY OUTCOMES subgroup data via PubMed.

That magnitude of benefit is why specialty society guidelines recommend PCSK9 inhibitors for very-high-risk ASCVD patients who fail to reach LDL-C <70 mg/dL on maximally tolerated statins plus ezetimibe. The ACC/AHA 2022 Chest Pain Guideline lists PCSK9 inhibitors as Class I recommendations for patients with recent ACS and insufficient LDL control. ACC/AHA 2022 Chest Pain Guideline via PubMed.

Indiana Medicaid Coverage for Praluent

Indiana Medicaid does not cover Praluent for the standard HeFH or ASCVD indications in 2026. The state's preferred drug list restricts PCSK9 inhibitor coverage to a narrow set of metabolic conditions tied to type 2 diabetes management, and even those approvals carry multi-step prior-authorization requirements.

The practical consequence: an Indiana Medicaid enrollee with HeFH who cannot afford $580/month cash has limited options through the state program. The Sanofi/Regeneron patient assistance program (PAP) is available to patients below 600 percent of the federal poverty level who lack coverage, and that program may be the only viable pathway for low-income uninsured Hoosiers who are not eligible for commercial-insurance savings cards.

Patients enrolled in Indiana's HIP 2.0 managed-care organizations (MCOs) such as MDwise, Anthem Medicaid, or CareSource should request a written coverage determination in writing before assuming the drug is excluded. MCO formularies are updated quarterly, and a small subset of plans have historically carved out coverage for HeFH with supporting genetic documentation. No guarantee of coverage exists, but a formal appeal supported by a lipidologist letter and ODYSSEY OUTCOMES data has succeeded in individual Indiana cases.

Commercial Insurance and Prior Authorization in Indiana

Virtually every Indiana commercial insurance plan that covers Praluent requires prior authorization. The standard criteria mirror ACC/AHA guideline thresholds:

1. Confirmed diagnosis of HeFH (genetic testing or Dutch Lipid Clinic criteria score of 6 or higher) or established ASCVD.
2. Documentation of maximally tolerated statin therapy for at least 90 days.
3. LDL-C remaining above 70 mg/dL (for ASCVD) or above 100 mg/dL (for HeFH) on that statin regimen.
4. A trial of ezetimibe 10 mg daily for at least 90 days (required by most Indiana BCBS, Anthem, and UnitedHealthcare plans).

Step-therapy requirements mean that some Indiana patients wait four to six months from initial cardiology referral to a first alirocumab injection, even when the clinical case is straightforward. Physicians who document ezetimibe intolerance with specific symptom records (myalgia, elevated hepatic enzymes) rather than general statements tend to see faster approvals.

Anthem Blue Cross and Blue Shield of Indiana, one of the state's largest commercial carriers, lists Praluent as a Tier 4 or Tier 5 specialty drug. After the deductible, the patient co-insurance is typically 25 to 33 percent of allowed cost, which can still approach $150 to $200/month before any savings card is applied.

The Regeneron/Sanofi Savings Card and Patient Assistance Programs

Sanofi and Regeneron jointly offer a copay savings card for commercially insured patients that can bring the out-of-pocket monthly cost to $0, subject to a per-year benefit cap. As of 2026, the cap sits at approximately $13,200 per year, which is enough to cover a full year at standard dosing for most patients. Praluent patient savings information via Sanofi/Regeneron product site, sourced at FDA label page.

The card is not available to patients whose primary insurance is a federal or state government program (Medicare, Medicaid, TRICARE, or the Indiana Health Coverage Programs). Indiana residents on Medicare Part D face the most difficult coverage situation: the Medicare redesign under the Inflation Reduction Act capped out-of-pocket drug costs at $2,000 per year starting in 2025, which helps, but PCSK9 inhibitors may still carry high Part D cost-sharing in the coverage gap depending on plan formulary tier.

The Sanofi Patient Assistance Program (PAP) operates separately from the savings card and provides Praluent at no charge to eligible uninsured or underinsured Indiana residents. Eligibility requires a household income at or below 600 percent of the federal poverty level and proof that no adequate insurance coverage exists. The application is submitted by the prescribing physician on behalf of the patient.

Compounded Alirocumab in Indiana: What Is Legal and What Is Available

Indiana 503A compounding pharmacies may legally prepare alirocumab preparations for individual patients when a valid prescription from a licensed prescriber exists. The FDA's framework for 503A pharmacies, outlined in Section 503A of the Federal Food, Drug, and Cosmetic Act, permits compounding of copies of commercially available drugs when there is a "specific medical need" that the commercial product cannot meet. FDA 503A compounding framework.

The practical test for Indiana patients is threefold. First, the prescribing physician must document a legitimate clinical reason why the commercial Praluent formulation is not appropriate for that patient (most commonly, cost-related inability to access the branded product). Second, the compounding pharmacy must source alirocumab active pharmaceutical ingredient (API) from an FDA-registered supplier. Third, the pharmacy must be licensed in Indiana under the Indiana Board of Pharmacy.

A decision framework for Indiana patients considering compounded alirocumab:

Step 1. Confirm the clinical indication meets FDA-approved criteria for alirocumab (HeFH or ASCVD with insufficient LDL control on maximally tolerated statins).

Step 2. Exhaust commercial insurance prior authorization and the Sanofi/Regeneron savings card. Compounding is most appropriate when those routes fail or are unavailable.

Step 3. Ask your prescriber to contact a licensed Indiana 503A compounding pharmacy that maintains quality-testing records for biologics. Not all 503A pharmacies compound monoclonal antibodies; call ahead to confirm capability.

Step 4. Confirm that the pharmacy uses a validated analytical method (HPLC or mass spectrometry) to verify alirocumab concentration and purity, because monoclonal antibodies are more complex to compound accurately than small-molecule drugs.

Step 5. Request a certificate of analysis (COA) for each compounded batch before administration.

Pricing for compounded alirocumab at licensed Indiana 503A pharmacies varies, but the competitor data indicates some providers currently quote $0/month for qualifying patients under specific access programs. Cash-pay pricing through private compounding channels typically ranges from $150 to $300 per month when out-of-pocket, representing a significant reduction from the $580 Praluent list price.

One important caveat: compounded alirocumab is not bioequivalent-tested under the same FDA standards as Praluent. The ODYSSEY OUTCOMES cardiovascular outcomes data applies to the branded product. Patients and prescribers should factor that distinction into the shared decision-making conversation.

Telehealth Prescribing of Alirocumab in Indiana

Indiana permits telehealth prescribing of Praluent by licensed physicians and advanced practice providers without an initial in-person visit, provided the prescriber conducts an adequate clinical evaluation via synchronous audio-video. Indiana Code 25-1-9.5 governs telehealth practice and does not carve out PCSK9 inhibitors or any other specialty lipid drug from remote prescribing.

The practical workflow for a HealthRX telehealth patient in Indiana:

1. Upload recent lipid panel (dated within 90 days), statin therapy documentation, and a summary of cardiovascular history through the patient portal.
2. Complete a synchronous video visit with the HealthRX prescriber.
3. Receive an electronic prescription sent to the patient's preferred Indiana pharmacy or, if eligible, to a partnered 503A compounding pharmacy.
4. A follow-up lipid panel four to eight weeks after first injection confirms LDL-C response and guides dose adjustment.

Most Indiana commercial labs (Quest, LabCorp, and hospital outpatient draw stations) can process a standard lipid panel plus PCSK9 activity level within 48 to 72 hours. Some cardiologists also request a high-sensitivity CRP at baseline to quantify residual inflammatory risk per the JUPITER trial framework. JUPITER trial via PubMed.

How Alirocumab Compares to Evolocumab (Repatha) in Indiana

Alirocumab and evolocumab are the only two FDA-approved PCSK9 inhibitors available in the United States. Both produce similar LDL-C reductions (45 to 60 percent from baseline on stable statin therapy), and both require prior authorization in Indiana under virtually identical criteria.

Repatha's list price in 2026 is approximately $560 to $580 per month, essentially matching Praluent's list. The Amgen SaveOnSP and Repatha patient programs mirror the Sanofi/Regeneron structure. The choice between the two drugs for most Indiana patients comes down to which product a given insurer places on a lower formulary tier, or which is available through a preferred compounding pharmacy.

The FOURIER trial (N=27,564) tested evolocumab in stable ASCVD patients and showed a 15 percent relative risk reduction in the primary composite endpoint at 2.2 years median follow-up (HR 0.85; 95% CI 0.79 to 0.92; P<0.001). FOURIER trial via PubMed. The effect size is statistically indistinguishable from ODYSSEY OUTCOMES, reinforcing guideline equivalence between the two agents.

Indiana prescribers who write alirocumab or evolocumab should specify the medical necessity reason on every prescription to accelerate pharmacy processing and reduce the chance of automatic substitution rejections.

LDL-C Targets and Monitoring After Starting Alirocumab in Indiana

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease recommends an LDL-C goal below 70 mg/dL for very-high-risk ASCVD patients and considers further reduction below 55 mg/dL reasonable when achievable. ACC/AHA 2019 Guideline via PubMed. The European Society of Cardiology goes further and recommends a target below 55 mg/dL for all very-high-risk patients, with a greater-than-50-percent LDL reduction from baseline as an additional benchmark. ESC 2019 Dyslipidaemia Guidelines via PubMed.

For an Indiana patient starting at LDL-C of 120 mg/dL on a maximally tolerated statin, the expected LDL-C after 75 mg alirocumab every two weeks is approximately 50 to 65 mg/dL, which meets both ACC/AHA and ESC targets. If the 12-week lipid panel shows LDL-C still above 70 mg/dL, dose escalation to 150 mg every two weeks is appropriate.

Monitoring schedule recommended by HealthRX for Indiana patients:

• Lipid panel at 4 to 8 weeks after initiation.
• Hepatic function tests at baseline and at 12 weeks (alirocumab does not carry a black-box liver warning, but baseline documentation protects against attribution of incidental liver enzyme elevations).
• Annual lipid panel thereafter for stable patients.
• Injection site reactions occur in approximately 7.2 percent of patients based on pooled ODYSSEY trial data and do not require drug discontinuation in most cases. Pooled ODYSSEY safety data via PubMed.

The American Heart Association's 2023 scientific statement on PCSK9 inhibitors notes that "PCSK9 inhibitors represent one of the most effective LDL-lowering interventions available, with a safety profile comparable to placebo in randomized trial data spanning more than 60,000 patient-years." AHA 2023 Scientific Statement via Circulation.

What Indiana Patients Should Do Before Their Next Cardiology Visit

Arriving prepared shortens the time from prescription to first injection. Bring printed lab results showing current LDL-C and the statin dose you have taken for at least 90 consecutive days. If you have tried ezetimibe and stopped due to side effects, document the symptom, the date you stopped, and whether you spoke with a physician. Insurers reviewing prior-authorization requests expect this level of detail.

Ask your cardiologist or telehealth provider to submit the prior-authorization request the same day as your visit. Turnaround for Indiana commercial plans averages 5 to 14 business days for standard review and 72 hours for expedited medical-necessity appeals. A peer-to-peer review call between your prescriber and the insurer's medical director resolves approximately 60 percent of initial denials in the PCSK9 inhibitor category, based on specialty pharmacy hub data reported by the National Lipid Association. NLA 2022 PCSK9 access data via NLA journal PubMed.

If coverage is denied and the Sanofi PAP does not apply, ask your prescriber explicitly whether a licensed Indiana 503A compounding pharmacy is an appropriate option given your clinical profile and LDL-C target.